Kusurinomadoguchi (5592) investor relations material

Executive summary

• Achieved record consolidated revenue of ¥12.33 billion for FY2026, up 10.1% year-over-year, driven by strong growth in media, "Minna no Okusuri Bako," increased prescription network usage, pharmaceutical distribution, and system adoption.

• Operating profit rose 37.3% to ¥2.68 billion, and net income attributable to parent increased 45.1% to ¥2.95 billion, reflecting cost optimization and successful M&A integration.

• EBITDA reached ¥4.19 billion, up 28% year-over-year, with EBITDA margin improving to 34%.

• Cash and cash equivalents increased by ¥3,133 million to ¥5.24 billion at year-end, mainly through short-term borrowing for working capital.

Financial highlights

• Stock revenue grew 18% year-over-year to ¥8.57 billion, offsetting a 5% decline in one-time (shot) revenue.

• Gross profit increased 7% to ¥6.97 billion, and operating profit margin improved to 22%.

• ROE rose to 29.8% (from 27.5% in FY2025), and EPS reached ¥263.23.

• Dividend per share increased to ¥38, with payout ratio at 14.4%.

• Total assets: ¥17.82 billion (+¥5.66 billion YoY); net assets: ¥11.46 billion (+¥2.95 billion YoY).

Outlook and guidance

• FY2027 guidance targets double-digit growth: revenue of ¥14.4 billion (+16.8%), operating profit of ¥3.1 billion (+15.6%), and net income of ¥3.1 billion (+5%).

• Dividend forecast for FY2027 is ¥40 per share, with a targeted payout ratio of 15%.

• Medium-term plan aims for ¥20 billion in stock revenue and over ¥5 billion in operating profit by FY2030.